News

OMAHA, Neb.–(BUSINESS WIRE)–Green Plains Inc. (NASDAQ: GPRE) today announced that Wayne Hoovestol, long-time Chairman of its Board of Directors (the “Board”) will retire at the end of his current term at the Annual Meeting of Shareholders, May 9. Hoovestol has served as a director on the Board since 2006 and Chairman since 2008. With Hoovestol’s retirement, the Board will be reduced from nine to eight directors, completing the board refreshment initiative announced in 2021, and will elect a new Chairperson following the Annual Meeting.

“Wayne has been an incredible champion for Green Plains and our stakeholders for the past 17 years; his insightful, thoughtful and steady leadership of the Board has been invaluable to Green Plains, especially as we transform the company,” said Todd Becker, President and CEO. “On behalf of the Board and all of our employees, we want to thank him for his years of dedicated service to the Board of Directors and the company. It has been an honor to work with Wayne since 2008 and I also want to personally thank him for his unwavering partnership and support.”

“Serving Green Plains as Board Chairman has been the honor, as well as the experience, of a lifetime,” said Hoovestol. “A special thanks to Green Plains executives and my fellow Board members, past and present, for the meaningful collaboration and shared commitment to the company’s success. I am excited for the future of Green Plains, as it is well-positioned to continue executing on its transformation under outstanding leadership.”

Hoovestol served as Green Plains’ Chief Operating Officer from January 2007 to February 2007, CEO from February 2007 to December 2008 and Chief Strategy Officer from March 2009 to November 2009. In 1978, he founded Hoovestol Inc., a trucking company that now operates as 10 Roads Express.

About Green Plains Inc.

Green Plains Inc. (NASDAQ:GPRE) is a leading biorefining company focused on the development and utilization of fermentation, agricultural and biological technologies in the processing of annually renewable crops into sustainable value-added ingredients. This includes the production of cleaner low carbon biofuels, renewable feedstocks for advanced biofuels and high purity alcohols for use in cleaners and disinfectants. Green Plains is an innovative producer of Ultra-High Protein and novel ingredients for animal and aquaculture diets to help satisfy a growing global appetite for sustainable protein. The Company also owns a 48.8% limited partner interest and a 2.0% general partner interest in Green Plains Partners LP. For more information, visit www.gpreinc.com.

Contacts

Investors: Phil Boggs | Executive Vice President, Investor Relations | 402.884.8700 | phil.boggs@gpreinc.com

Media: Lisa Gibson | Communications Manager | 402.952.4971 | lisa.gibson@gpreinc.com

March 29 (Reuters) – Concentrix Corp (CNXC.O) will buy Paris-based outsourcing and consultancy firm Webhelp in a $4.8 billion deal, the business services provider said on Wednesday, to expand outside North America and add clients in fast-growing markets.

Webhelp specializes in sales, marketing and payment services across Europe, Latin America and Africa, and will bring about 1,000 new clients, the company said.

The combined company is expected to have $9.8 billion in revenue for fiscal year 2023 on a pro forma basis, and will be headed by Concentrix CEO Chris Caldwell.

“The combination of these two companies allows us to take even more access to the $550 billion expanded marketplace we compete in,” Caldwell said on a conference call.

Shares of California-based Concentrix were down more than 7% in extended trading. Separately, the company also posted an over 20% slide in first-quarter net income to $87.9 million. Revenue rose 6.5% to $1.64 billion.

Webhelp will receive 14.9 million shares of Concentrix, 500 million euros ($542 million) in cash, and a 700-million euros note payable in two years, the company said.

Webhelp’s targeted net debt of about 1.55 billion euros will also be refinanced when the transaction closes.

Concentrix shareholders will own about 78% of the combined company and Webhelp shareholders the rest after the deal closes, which is expected by the end of the year.

The company expects cost benefits of $75 million in the first full year after closing, with the deal adding to adjusted earnings per share at the end of that period.

($1 = 0.9226 euros)

Reporting by Deborah Sophia in Bengaluru; Editing by Sriraj Kalluvila

Our Standards: The Thomson Reuters Trust Principles.

CARLSBAD, Calif., March 29, 2023 /PRNewswire/ — Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced that management will present and participate in the following investor conferences:

@media screen and (min-width: 1201px) {
.jhuyz6424a118ed839 {
display: block;
}
}
@media screen and (min-width: 993px) and (max-width: 1200px) {
.jhuyz6424a118ed839 {
display: block;
}
}
@media screen and (min-width: 769px) and (max-width: 992px) {
.jhuyz6424a118ed839 {
display: block;
}
}
@media screen and (min-width: 768px) and (max-width: 768px) {
.jhuyz6424a118ed839 {
display: block;
}
}
@media screen and (max-width: 767px) {
.jhuyz6424a118ed839 {
display: block;
}
}

Related

FRANKFURT (Reuters) -German unlisted drugmaker Boehringer Ingelheim said on Wednesday its operating income rose 1.4% in 2022, as more prescriptions of diabetes drug Jardiance trumped higher energy and development costs.

Family-owned Boehringer said in its annual report that full-year operating income came in at 4.77 billion euros ($5.17 billion), up from 4.71 billion a year earlier.

The Jardiance group of products, managed in a partnership with Eli Lilly, made 5.8 billion euros in sales, a currency-adjusted surge of 39.1%.

The diabetes treatment is increasingly used to cut the risk of cardiovascular disease in diabetic patients and it also won approval as a treatment for heart failure early in 2022.

Apart from higher material and energy costs, earnings growth was tempered by expenses for large clinical trials and write-downs on development projects.

“The strong business results are laying the foundation for the funding of our late-stage pipeline, of mid-term growth opportunities and of further investment in new technologies,” said the group’s finance chief Michael Schmelmer.

Boehringer and Lilly said last November that Jardiance was shown to also slow the progression of chronic kidney disease, as the partners seek to catch up with market segment leader AstraZeneca with its kidney drug Farxiga.

Sales of pulmonary fibrosis drug Ofev rose a currency-adjusted 20.6% to 3.2 billion euros, Boehringer said.

For 2023, Boehringer predicted a slight increase in operating income.

($1 = 0.9232 euros)

(Reporting by Ludwig Burger and Patricia WeissEditing by Louise Heavens and Mark Potter)

East West Bancorp, Inc. Earns #1 Spot in S&P Global Market Intelligence Ranking

S&P Global Market Intelligence Ranks East West Bancorp Inc. Best Performing U.S. Public Bank in 2022

PASADENA, Calif.–(BUSINESS WIRE)–
East West Bancorp, Inc. (“East West” or the “Company”) (Nasdaq: EWBC), parent company of East West Bank, announced it has earned the number one spot in the 2022 Ranking of U.S. Public Banks by Financial Performance. This annual analysis by S&P Global Market Intelligence assesses the financial performance of publicly held banks with more than $10 billion in assets across the nation.

S&P Global Market Intelligence first launched the annual rankings list in 2011 to assess the performance of banks based on returns, growth and efficiency, and places a premium on the strength and risk profile of balance sheets. East West secured the top spot in 2022, outperforming the industry on the combined metrics.

“We are honored to be named the top public bank in the United States by S&P Global Market Intelligence,” said East West Bancorp Inc. Chairman and CEO Dominic Ng. “As the bank celebrates its 50th anniversary in 2023, this achievement serves as a reminder of our continued legacy of remaining steadfast amid volatile market conditions. I remain grateful to our over 500,000 customers who continue to put their trust in us.”

East West’s conservatively managed balance sheet, strong capital and liquidity levels form a solid and stable foundation. These strengths, along with our diversified customer base and business model, allow us to have industry-leading profitability and high-quality earnings year after year. We look beyond our fifty years of history with the commitment to helping our customers build new bridges of opportunity and reach further. For more information or to set up a press interview, please contact [email protected].

About East West

East West Bancorp, Inc. is a public company with total assets of $64.1 billion and is traded on the Nasdaq Global Select Market under the symbol “EWBC”. The Company’s wholly-owned subsidiary, East West Bank, is the largest independent bank headquartered in Southern California, operating over 120 locations in the United States and in Asia. The Company’s markets in the United States include California, Georgia, Illinois, Massachusetts, Nevada, New York, Texas and Washington. For more information on East West, visit the Company’s website at www.eastwestbank.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230329005862/en/

Janie Beaman

[email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Banking Asset Management Professional Services Finance

MEDIA:

Logo

PRAGUE–(BUSINESS WIRE)–Westinghouse Electric Company and CEZ signed an agreement to supply VVER-440 fuel assemblies at the Dukovany Power Plants. Westinghouse will deliver fuel beginning in 2024, replacing the current supplier, with an anticipated term of seven years.

This important contract builds on the long-standing partnership between the two companies and a recent agreement to provide modified Robust Westinghouse Fuel Assemblies (RWFA) for the Temelin nuclear power plant.

“Our focus is not only the safety of our nuclear power plants, but also the energy safety of the entire Czech Republic. That´s why the contract with Westinghouse is very important. Thanks to the widening of the number of possible suppliers, we are strengthening our energy independence and the certainty of further operation of our sources,” said Bohdan Zronek, a member of the Board of Directors at CEZ and Director of the Nuclear Energy Division.

“We are grateful for CEZ Group’s confidence in Westinghouse and remain fully committed to supporting its policy of supply diversification,” said Tarik Choho, President, Westinghouse Nuclear Fuel. “Westinghouse is delivering a true alternative with a proven fuel design for the VVER plants, and we look forward to reinforcing our long-term collaboration with CEZ.”

Westinghouse is deeply committed to helping the Czech Republic and other countries achieve the goal of a cleaner, more secure energy future. The company has been working for more than a decade to supply VVER-type reactors.

Westinghouse Electric Company is shaping the future of carbon-free energy by providing safe, innovative nuclear and other clean power technologies and services globally. Westinghouse supplied the world’s first commercial pressurized water reactor in 1957 and the company’s technology is the basis for nearly one-half of the world’s operating nuclear plants. Over 135 years of innovation make Westinghouse the preferred partner for advanced technologies covering the complete nuclear energy life cycle. For more information, visit www.westinghousenuclear.com and follow us on Facebook, LinkedIn, and Twitter.

Contacts

media@westinghouse.com